ANIK - NASDAQ
Anika Therapeutics, Inc.
$14.41
+0.49%Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
At a Glance
Live SnapshotAnika Therapeutics, Inc. Management Team
Mr. Stephen D. Griffin
Executive Vice President, Chief Financial Officer & Treasurer
Compensation
$795,171
Mr. David Colleran J.D.
Executive Vice President, General Counsel & Corporate Secretary
Compensation
$685,104
Dr. Cheryl Renee Blanchard Ph.D.
President, Chief Executive Officer & Director
Compensation
$1,270,358
Mr. James Chase
Senior Vice President of International Sales & Marketing
Ms. Mira Leiwant
Senior Vice President of Regulatory, Quality & Clinical Affairs
Mr. Ian W. McLeod
Vice President & Chief Accounting Officer
Mr. Ben Joseph
Vice President of Commercial & Corporate Development
Ms. Lisa Funiciello
Vice President of Human Resources
Mr. Mark Namaroff
Vice President of Investor Relations, ESG & Corporate Communications
Anika Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $223K worth of ANIK shares, with no selling activity reported.
3 Months
17.2K
223.20K
0
0.00
+223K
+$223K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Griffin Stephen D.
Director, Officer: President And Ceo
$150K
Henneman John B Iii
Director
$73K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $223K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
2 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
ANIK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 18, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 20, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | June 11, 2024 | July 09, 2024 | 2024 | |
DEF 14A DEF 14A N/A | May 01, 2023 | May 01, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 08, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | June 16, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 16, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 25, 2019 | June 18, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 17, 2018 | May 31, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 28, 2017 | June 13, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.